EP1627645B1 - Agent antitumeur et son procede de production - Google Patents

Agent antitumeur et son procede de production Download PDF

Info

Publication number
EP1627645B1
EP1627645B1 EP04707295.4A EP04707295A EP1627645B1 EP 1627645 B1 EP1627645 B1 EP 1627645B1 EP 04707295 A EP04707295 A EP 04707295A EP 1627645 B1 EP1627645 B1 EP 1627645B1
Authority
EP
European Patent Office
Prior art keywords
tumor agent
sma
polymeric
agent according
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04707295.4A
Other languages
German (de)
English (en)
Other versions
EP1627645A4 (fr
EP1627645A1 (fr
Inventor
Hiroshi Maeda
Khaled Greish
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1627645A1 publication Critical patent/EP1627645A1/fr
Publication of EP1627645A4 publication Critical patent/EP1627645A4/fr
Application granted granted Critical
Publication of EP1627645B1 publication Critical patent/EP1627645B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to a group of polymeric antitumor agents, forming high molecular weight micelles complex, having selective tumor targeting capacity and long term retention in tumor, thereby exhibiting highly effective cancer treatment with greatly reduced side effects to the normal organs and tissues.
  • the present invention relates to high molecular weight polymeric antitumor agents, forming high molecular weight micelles complex by molecular binding or interaction of low molecular weight antitumor agents, such as anthracyclin or platinum derivative with styrene-maleic acid copolymer (hereinafter referred to SMA).
  • low molecular weight antitumor agents such as anthracyclin or platinum derivative with styrene-maleic acid copolymer (hereinafter referred to SMA).
  • the present invention also relates to the method of manufacturing the same.
  • Anthracyclins antibiotics are known for their potent cytotoxic effect that is known to involve multiple mechanisms of cell killing. Generation of the oxygen radical by quinone group in its molecule promotes its DNA intercalating property and topoisomerase inhibitory mechanisms. All these effects lead to potent cancer cell killing. Pirarubicin, being relatively a new member of this group, has its unique DNA and RNA synthesis inhibitory action, more active than doxorubicin, with reduced cardiotoxicity.
  • the tissue distribution of drug plays a crucial role.
  • drugs of low molecular weight drugs for example, molecular size less than 10 KDa
  • drugs of low molecular weight drugs are readily distributed in various normal organs tissues or tumor tissues indiscriminately through simple diffusion, and they are eventually eliminated into the bile by the liver and/or into urine through renal excretion.
  • doxorubicin and pirarubicin with molecular weight of 543.5 and 627.6, respectively, their distribution in the normal organs, i.e. the cardiac or bone marrow tissues, limit the effective use at high dose of these low molecular weight drugs for complete tumor eradication.
  • EPR phenomenon is attributed to anatomical and pathophysiological alternations in tumor tissues, such as increased vascular density by angiogenesis, lack of smooth muscle layer in solid tumor vessels and impaired lymphatic recovery.
  • Pathophysiological changes in solid tumor are brought about by extensive production of vascular mediators such as bradykinin, nitric oxide, prostaglandins, matrix metalloproteinases (MMPs), VEGF / VPF and others resulting in enhancement of EPR effect that are not seen in normal tissues (e.g. Cancer Res., 58, 159-165, 1995 ; J. Control. Release, 74, 47-61, 2001 ; Advan. Enzyme Regul., 41, 189-207, 2001 )
  • MMPs matrix metalloproteinases
  • SMA poly (styrene-co-maleic anhydride half n-butyrate)] conjugate with covalently linked to the proteinaceous antitumor agent, neocarzinostatin (NCS), which is named SMANCS (Japanese Patent (JP) No.1,549,302 , JP 1,545,131 , JP 2,556,865 and U.S.Patent 2,556,865 ). This was the first antitumor polymeric drug in the world.
  • SMA confers unique pharmacological characters when compared with the parent low molecular weight drugs. Namely, SMA conjugates would become capable of rapid non-covalent bond to albumin, and hence that confers tumor tropism by EPR effect by virtue of increase of the molecular weight, thereby has excellent tumor targeting capacity.
  • the inventors of present invention aimed at a method for improving selective solid tumor targeting capacity of antitumor agents such as anthracyclins which affect normal cells adversely, accordingly reduce the side effects.
  • antitumor agents such as anthracyclins which affect normal cells adversely, accordingly reduce the side effects.
  • SMA polymer was attempted to attach to antitumor agents, unique polymeric antitumor agent was obtained; these drugs formed micelle complex so that it behaves as a polymer and indicates EPR effect more extensively, resulting in improved antitumor effect and lesser side effects, and also better stability at room temperature, in contrast to SMANCS which is prepared by polymerization based on mere covalent bond of SMA and NCS.
  • Drugs other than anthracyclin, such as cis-platinum form polymeric micelle complex by combining with SMA, thus obtained polymeric antitumor agents also have selective solid tumor targeting capacity
  • the present invention relates to polymeric antitumor agent, which forms polymeric micelle complex by combining low molecular weight antitumor agent with SMA, according to the claims. More preferably, the present invention relates to polymeric antitumor agent, which forms polymeric micelle complex by combining SMA and anthracyclins antitumor agents, such as pirarubicin, doxorubicin, or cis-platinum.
  • anthracyclins antitumor agents are preferred.
  • Anthracyclins antitumor are antibiotics having glycoside structure of 7,8,9,10-tetrahydro-5,12-naphthasenquinone of which structure are illustrated in Formula (1) and (2).
  • Example of Anthracyclins may be pirarubicin, doxorubicin, epirubicin daunorubicin or acrarbicin. Among them, doxorubicin (Formula (1)) and pirarubicin (Formula (2)), are more preferred.
  • Cis diamine dichloro platinum illustrated by Formula (3) is an antitumor agent called cis-platinum.
  • cis-platinum an antitumor agent
  • Such a heavy metal chelate, as well as alkaloids such as camptothecin, taxol and the like can also form SMA micelle complex to be polymeric antitumor agents.
  • SMA which is the polymerizing agent in the present invention is obtained by copolymerization of styrene with maleic acid. Since SMA is copolymer having styrene and maleic acid as indispensable ingredient, it has basically monomer unit of styrene shown by the formula(4), but monomer unit of maleic acid may be partially half alkyl or acyl esters or maleic anhydride as shown by the formula(5)( Maeda H. et al., J. Med.Chem, 28, 455-61, 1980 ).
  • R in the formula (5) is alkyl or acyl residue of carbon 1 ⁇ 4.
  • half alkyl esterized styrene-maleic acid copolymer, of which a part of R is butyl residue, may be favorably used.
  • SMA can have various molecular weight range
  • most preferable size of SMA used as polymerizing agent in the present invention is from trimmer (about 660 Da) to above 40 KDa
  • SMA doxorubicin complexes or conjugates
  • SMA also have multiple functional carboxylic group (e.g. ⁇ 14 groups per chain of 7 repeating units), which can be utilized to react to cross-link with amino or hydroxyl group of multiple compounds.
  • Another added advantage of the invented SMA-anthracyclin polymeric drugs is related to its acquired lympho-tropic characteristics that become advantageous against lymphatic metastasis. Namely, high distribution in the lymphatics was observed ( H. Maeda et al, Gann, 73, 278-284, 1982 ).
  • This copolymer of styrene and maleic acid has favorable biological properties such as capacity to rapidly make non-covalent bond to albumin ( Kobayashi et al., J. Bioactiv. Compat. Polymer, 3, 319-333, 1988 ), tumor tropism ( Maeda H., Matsumura Y., Cancer Res., 46, 6387-6392, 1986 ), and immunopotentiation ( Oda T. et al., Proc. Soc. Ex.Biol. Med., 181, 9-17, 1986 ).
  • SMA facilitated highly enhanced the cellular uptake due to existence of styrene and maleic acid ( Oda T. et al, J. Nat. Cancer Inst., 79, 1205-1211, 1987 ).
  • Non-covalent bond such as ionic bond or hydrogen bond can be also achieved by the reaction in the presence of amino acids or polyamine to the mixture at pH7 or lower pH, preferably at pH of 2-5, under stirring.
  • L- arginine, L-ornitine, or lysine are used as amino acid, among them L- arginine is most preferable.
  • Spamine and spamidine are most preferable among the polyamine.
  • polymeric antitumor agent in the present invention does not require any additives, such as surfactants for micellization.
  • antitumor agent and SMA alone are used for stable micelle formation of SMA-antitumor agent micelle complex. Dehydration condensation reaction process is not needed to form micelle complex. This is one of the advantages of the present invention.
  • Polymeric micelle complex in the present invention may be formed by the reaction of low molecular weight drug and SMA (hydrolyzed), so that the drug is trapped in the micelle.
  • the drug is bonded through either cross-link by covalent bond with SMA, ionic bond or non-ionic bond directly.
  • SMA covalent bond with SMA
  • ionic bond ionic bond
  • non-ionic bond directly.
  • SMA micelle complex thus obtained has unique pharmacological properties compared with parent low molecular weight antitumor agents. Firstly, it has selective delivering ability to the tumor tissues and long term releasing ability verified by the EPR effect, therefore, high therapeutic concentration in tumor tissues with high durability is attained. Moreover, it secures the physiological functions of normal critical organs and tissues, such as cardiac tissue, the bone marrow, or the kidney. It does not exist in parent low molecular weight antitumor agents. The higher safety in animal models as described herein was also confirmed.
  • the SMA-micelle complex according to the present invention has the capacity to bind with plasma proteins, such as albumin, fibrin or lipoprotein, predominantly, it rapidly forms non-covalent bond with albumin.
  • plasma proteins such as albumin, fibrin or lipoprotein
  • aqueous formulation for iv and oily formulation, especially lipiodole formation for intra arterial or oral delivery, and other various administration method may be applied.
  • Negative charge would enable prolonged in vivo half-life in contrast to positively charged polymers that usually have very short in vivo half-life.
  • Apparent molecular weight of the micelle complex in the present invention may be greater than 10Kda, preferably greater than 50KDa for the purpose of the invention.
  • the apparent molecular weight is defined as complex through inter molecule mutual affinity, determined by molecule sieve method, ultra filtration method, ultracentrifugation method or light scattering method in the solution.
  • SW480 and HeLa cells were then incubated in the presence of native doxorubicin, pirarubicin or its SMA-complexes for 72 hours. Cytotoxicity was then quantified as the fraction of surviving cells relative to drug untreated controls ( Figure 5 ).
  • SMA-pirarubicin exhibited almost similar cytotoxic effect in vitro to these cell lines when compared to free pirarubicin (i.e. 85-100%). Cytotoxic activity of the SMA-doxorubicin micelle were considerably lower than that of the free doxorubicin (about 40%) which can be attributed to the higher hydrophobic property of doxorubicin having slower release rate, thus delaying the release of free drug available to cells in the culture medium.
  • SMA-anthracyclins polymer complexes have potential activity comparable to free parent drugs, or in case of doxorubicin, the activity was lower than free drug as seen in Doxorubicin.
  • Tumor used was colon 38 adenocarcinoma originated from colon cancer.
  • Tumor tissue of colon 38 tumor cells in block of about 30mg/ site was implanted bilaterally in dorsal skin of C57 BL mice.
  • drug treatments were initiated using 50mg/kg pirarubicin equivalent complex in a single dose administered i.v.
  • Results showed that 100 % of animals attained total recovery after 2 weeks of treatment, further demonstrating the promising potentiality of those agents. Results are shown in Figure 8 .
  • ALT alanine aminotransferase
  • AST aspartate aminotransferase
  • LDH lactic dehydrogenase
  • CPK total creatine phosphokinase
  • micellar drugs showed no toxicity up to 100mg/kg body weight when administered on 4 time injections (25mg/kg x 4) over one week, or 70 mg/kg when administered as a single dose. Blood count, cardiac and liver functions in animal receiving the complexes micellar drugs showed no significant difference from any drugs treated control animals.
  • Table 1 shows an example of complete blood count of animals for 3 weeks after drug administration, iv receiving 10mg/kg of free pirarubicin versus animals receiving 20mg/kg SMA-pirarubicin complex (20mg/kg free pirarubicin equivalent), compared to no drug control in mice Remarkable safety of the drugs of the present invention should be noted which makes it highly promising for clinical trails.
  • Human mammary cancer cell was incubated in SMA-cisplatinum micelle complex (25 and 50 ⁇ g/ml) solution in a test tube for 72 hours in the same way as example 3.
  • the cytotoxicity was expressed as ratio of survived cell together with those of no drug and free cis-platinum in Figure 10 .
  • SMA cis-platinum micelle complex indicated its cytotoxicity against the above described tumor cell at the same extent as free cis-platinum.
  • Gel filtration condition is same as Example 2, except that, the column size used was 52x1.5 cm, with 0.2 M sodium hydrogen bicarbonate buffer (pH 8.1) as mobile phase.
  • the SMA-taxol micelle eluted at void volume indicating the size larger than 10 kDa.
  • Standard molecular weight substance in the top of Figure 11 is BSA (Bovine serum albumin) (67.5Kda) and phenol red (354Kda)
  • the antitumor agent according to the present invention may improve cancer treatment effect and reduce side effects to the normal organs and tissues to a large extent, by forming high molecular weight micelle complex of SMA and low molecular weight antitumor agent which itself has strong antitumor effect but little selective targeting to tumor cells.
  • stable micelle complex may be formed from SMA, antitumor agent and polyamines.
  • the complex behaves as if 10kDa or greater molecular weight polymer in human body. Further when it bind albumin through non-covalent bonding, it indicates apparent increase in molecular weight, so that it may be concentrated in tumor cells.
  • the present invention enables ten times as strong antitumor effect as low molecule antitumor agent against various cancer with minimum side effect, so that it is promising therapeutic drug for solid cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

  1. Agent antitumoral polymérique, comprenant un copolymère styrène-acide maléique (SMA) et un agent antitumoral,
    caractérisé en ce que
    la masse moléculaire de l'agent antitumoral est inférieure à 10 kDa, de sorte que l'agent polymère antitumoral forme un complexe micellaire polymérique, dans lequel l'agent antitumoral est lié au SMA par une liaison non covalente, et l'agent antitumoral est incorporé dans la micelle.
  2. Agent antitumoral polymérique selon la revendication 1, dans lequel l'agent antitumoral est une anthracycline.
  3. Agent antitumoral polymérique selon la revendication 2, dans lequel l'anthracycline est la doxorubicine ou la pirarubicine.
  4. Agent antitumoral polymérique selon la revendication 1, dans lequel l'agent antitumoral est le cisplatine ou un alcaloïde.
  5. Agent antitumoral polymérique selon l'une des revendications 1 à 4, dans lequel la masse moléculaire de l'agent antitumoral polymérique est supérieure à 10 kDa.
  6. Agent antitumoral polymérique selon l'une des revendications 1 à 5, dans lequel l'unité monomère d'acide maléique est partiellement une moitié d'ester d'alkyle ou d'acyle ou est l'anhydride maléique.
  7. Agent antitumoral polymérique selon la revendication 6, dans lequel l'unité monomère d'acide maléique est à moitié estérisée avec un radical alkyle ou acyle de 1 à 4 atomes de carbone.
  8. Agent antitumoral polymérique selon la revendication 6 ou 7, dans lequel le copolymère styrène-acide maléique (SMA) est à moitié estérisé, dans lequel une partie des groupes alkyle consiste en des groupes butyle.
  9. Agent antitumoral polymérique selon l'une des revendications 1 à 8, dans lequel la masse moléculaire du copolymère styrène-acide maléique (SMA) est de 660 Da à 40 kDa ou supérieure.
  10. Procédé de préparation de l'agent antitumoral polymérique selon l'une des revendications 1 à 9, comprenant :
    - la dissolution d'un copolymère styrène-acide maléique et d'un agent antitumoral dans de l'eau, des acides aminés ou une polyamine à un pH de 7 ou inférieur, pour obtenir une solution aqueuse ; puis
    - l'augmentation du pH à plus de 8 pour déprotoner les groupes amino libres ; suivie de
    - la neutralisation ; et finalement
    - la récupération d'une fraction de polymère par un procédé de séparation des polymères.
  11. Procédé selon la revendication 10, dans lequel la dissolution est réalisée à un pH de 2 à 5, de préférence sous agitation.
  12. Procédé selon la revendication 10 ou 11, dans lequel l'augmentation du pH est réalisée jusqu'à un pH de 10 à 12.
  13. Procédé selon l'une des revendications 10 à 12, dans lequel la récupération est réalisée en utilisant l'ultrafiltration et/ou la chromatographie sur colonne.
  14. Agent antitumoral polymérique selon l'une des revendications 1 à 9, pour utilisation dans une méthode de traitement du cancer.
  15. Utilisation de l'agent antitumoral polymérique selon l'une des revendications 1 à 9 pour la fabrication d'un médicament destiné au traitement du cancer.
EP04707295.4A 2003-05-26 2004-02-02 Agent antitumeur et son procede de production Expired - Lifetime EP1627645B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003147852 2003-05-26
PCT/JP2004/000993 WO2004103409A1 (fr) 2003-05-26 2004-02-02 Agent antitumeur et son procede de production

Publications (3)

Publication Number Publication Date
EP1627645A1 EP1627645A1 (fr) 2006-02-22
EP1627645A4 EP1627645A4 (fr) 2008-12-24
EP1627645B1 true EP1627645B1 (fr) 2017-08-23

Family

ID=33475378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04707295.4A Expired - Lifetime EP1627645B1 (fr) 2003-05-26 2004-02-02 Agent antitumeur et son procede de production

Country Status (11)

Country Link
US (1) US7682630B2 (fr)
EP (1) EP1627645B1 (fr)
JP (1) JP4669393B2 (fr)
CN (1) CN1697663A (fr)
AU (1) AU2004241830B9 (fr)
CA (1) CA2489259C (fr)
ES (1) ES2642179T3 (fr)
HU (1) HUE035003T2 (fr)
PT (1) PT1627645T (fr)
TW (1) TW200505414A (fr)
WO (1) WO2004103409A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112361A1 (fr) * 2005-04-18 2006-10-26 Hiroshi Maeda Agent pharmaceutique polymere pour le traitement du cancer et son processus de production
WO2007031888A2 (fr) * 2005-09-12 2007-03-22 Bendale N Yogesh Nouveau platine biologique, procede de preparation et procede d'administration pour un traitement antitumoral
FR2922452B1 (fr) * 2007-10-19 2010-01-22 Coatex Sas Formulations de composes organoplatiniques en presence de polymeres associatifs, produits obtenus et leurs utilisations
JP2010013411A (ja) * 2008-07-05 2010-01-21 Hiroshi Maeda 抗炎症剤
PT2774625T (pt) 2011-09-05 2017-06-22 Maeda Hiroshi Sonda molecular fluorescente do tipo polímero
JP6083738B2 (ja) * 2013-03-06 2017-02-22 公立大学法人大阪市立大学 ホウ素中性子捕捉療法用組成物およびその製造方法
WO2015088990A1 (fr) 2013-12-09 2015-06-18 Durect Corporation Complexes de principes pharmaceutiquement actifs, complexes de polymères, et compositions et procédés les impliquant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0087957B1 (fr) 1982-02-27 1986-11-26 Kuraray Co., Ltd. Complexes de néocarzinostatine, méthode pour leur production, et agent antitumeur contenant ces complexes comme composant actif
JPS58149903A (ja) * 1982-02-27 1983-09-06 Kuraray Co Ltd ネオカルチノスタチン複合体の製造法
JPS6075499A (ja) 1983-08-08 1985-04-27 Kuraray Co Ltd ネオカルチノスタチン誘導体及びその製造法
JP2556865B2 (ja) * 1986-09-19 1996-11-27 山之内製薬株式会社 ネオカルチノスタチン誘導体の非注射投与用組成物
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
DK0914116T3 (da) * 1996-05-22 2000-11-20 Protarga Inc Kompositstoffer omfattende konjugater af cis-docosahexaensyre og Taxotere
GB0001481D0 (en) * 2000-01-21 2000-03-15 Theryte Ltd System for delivering a medicament
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JPWO2004103409A1 (ja) 2006-07-20
EP1627645A4 (fr) 2008-12-24
US20050208136A1 (en) 2005-09-22
HUE035003T2 (en) 2018-05-02
CA2489259A1 (fr) 2004-12-02
US7682630B2 (en) 2010-03-23
AU2004241830B9 (en) 2010-04-22
CA2489259C (fr) 2011-08-30
TWI332834B (fr) 2010-11-11
ES2642179T3 (es) 2017-11-15
AU2004241830B2 (en) 2010-02-25
CN1697663A (zh) 2005-11-16
WO2004103409A1 (fr) 2004-12-02
JP4669393B2 (ja) 2011-04-13
TW200505414A (en) 2005-02-16
AU2004241830A1 (en) 2004-12-02
PT1627645T (pt) 2017-11-23
EP1627645A1 (fr) 2006-02-22

Similar Documents

Publication Publication Date Title
Melnyk et al. Therapeutic potential of polypeptide-based conjugates: rational design and analytical tools that can boost clinical translation
Greish et al. SMA–doxorubicin, a new polymeric micellar drug for effective targeting to solid tumours
Albuquerque et al. pH-responsive polymersome-mediated delivery of doxorubicin into tumor sites enhances the therapeutic efficacy and reduces cardiotoxic effects
Saisyo et al. pH-sensitive polymeric cisplatin-ion complex with styrene-maleic acid copolymer exhibits tumor-selective drug delivery and antitumor activity as a result of the enhanced permeability and retention effect
US8466127B2 (en) Pegylated and fatty acid grafted chitosan oligosaccharide, synthesis method and application for drug delivery system
JP2000509394A (ja) 細胞膜を横切って物質を輸送するためのポリペプチド結合体
WO1996016541A1 (fr) Agents biologiques lies a des polymeres
JP2003531930A (ja) 両親媒性大環状誘導体およびそれらの類似体
CN102292069A (zh) 囊泡制剂
JP4522452B2 (ja) 高分子型癌治療用医薬およびその製造方法
EP1627645B1 (fr) Agent antitumeur et son procede de production
WO2014155145A1 (fr) Nanocomposition stable comprenant de l'épirubicine, procédé pour sa préparation, son utilisation et compositions pharmaceutiques la contenant
EP3453390B1 (fr) Composition pharmaceutique contenant un médicament polymérisé
WO2012066581A4 (fr) Nouveaux conjugués pour administration ciblée de médicaments
WO2018038155A1 (fr) Micelle et utilisation de cette dernière
CN102652836A (zh) 靶向释药的抗癌蛋白质或多肽聚合物前药及其制备方法
CN113244175B (zh) 一种免疫囊泡美登素偶联物及其制备方法与应用
JP3283543B2 (ja) 脂溶性肝疾患治療薬とｐｖｌａとの包接化合物
ITPD20090168A1 (it) Coniugati polimerici fosfolipidi
Martins et al. Intelligent delivery of antitumor drugs mediated by polymeric nanomicelles: a review
US20130259944A1 (en) Methods and compositions for treating cancer with platinum particles
Chen The self-assembly and characterization of camptothecin-dilysine/polydopamine/Indocyanine-green nanotubes
Bhanu Malhotra et al. Polymer-drug conjugates: targeted drug delivery.
JP2023533722A (ja) ナノ粒子およびその製造方法
JP2002371016A (ja) インターフェロン−高分子複合体及びその医薬用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAEDA, HIROSHI

Inventor name: GREISH, KHALED

A4 Supplementary search report drawn up and despatched

Effective date: 20081121

17Q First examination report despatched

Effective date: 20090325

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20161205

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602004051696

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0047480000

Ipc: A61K0047580000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20170125

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/69 20170101ALI20170113BHEP

Ipc: A61K 47/58 20170101AFI20170113BHEP

Ipc: A61K 47/32 20060101ALI20170113BHEP

Ipc: A61P 35/00 20060101ALI20170113BHEP

Ipc: A61K 47/18 20170101ALI20170113BHEP

Ipc: A61K 45/06 20060101ALI20170113BHEP

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170616

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 920631

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004051696

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2642179

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171115

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOHEST AG, CH

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 1627645

Country of ref document: PT

Date of ref document: 20171123

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171116

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171124

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E035003

Country of ref document: HU

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004051696

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180202

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 920631

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170823

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20191219

Year of fee payment: 17

Ref country code: PT

Payment date: 20191220

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20191231

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20200113

Year of fee payment: 17

Ref country code: AT

Payment date: 20200211

Year of fee payment: 17

Ref country code: DE

Payment date: 20200127

Year of fee payment: 17

Ref country code: ES

Payment date: 20200302

Year of fee payment: 17

Ref country code: HU

Payment date: 20200110

Year of fee payment: 17

Ref country code: NL

Payment date: 20200226

Year of fee payment: 17

Ref country code: GB

Payment date: 20200225

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20200129

Year of fee payment: 17

Ref country code: CH

Payment date: 20200219

Year of fee payment: 17

Ref country code: BE

Payment date: 20200116

Year of fee payment: 17

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170823

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004051696

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 920631

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210202

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210202

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210202

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210202

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210802

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210901

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210202

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210202

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210202

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210203

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210228